MAOA and Parkinson disease: MAOIs havebeen developed as therapeutic agents in two key categories, basedon the substrate specificity and the distribution differences of thetwo enzyme isoforms in neuronal tissues. MAO-A selective inhibitors are used to treat mental disorders, suchas anxiety and depression, whereas MAO-B selective inhibitors areprimarily employed to manage neurodegenerative diseases like Alzheimer’sdisease and Parkinson’s disease.,,